Summary
Regeneron Pharmaceuticals, Inc. (REGN) reported a significant turnaround in its financial performance for the nine months ended September 30, 2012, transitioning from a net loss in the prior year to a substantial net income. This shift is primarily driven by the successful launch and strong sales of EYLEA® (aflibercept) Injection for ophthalmological conditions, which began in November 2011. The company also benefited from milestone payments related to ZALTRAP® (ziv-aflibercept) Injection and EYLEA approvals in new markets. Operating expenses saw an increase, largely due to expanded headcount and commercialization efforts for EYLEA, alongside ongoing investments in research and development for its robust pipeline of antibody-based and trap-based drug candidates. The company maintains a strong cash and marketable securities position, indicating financial stability to support its ongoing development and commercialization activities.
Financial Highlights
45 data points| Revenue | $427.69M |
| Cost of Revenue | $20.14M |
| Gross Profit | $407.54M |
| R&D Expenses | $158.29M |
| SG&A Expenses | $46.88M |
| Operating Expenses | $225.32M |
| Operating Income | $202.36M |
| Interest Expense | $11.41M |
| Net Income | $191.47M |
| EPS (Basic) | $2.02 |
| EPS (Diluted) | $1.72 |
| Shares Outstanding (Basic) | 95.01M |
| Shares Outstanding (Diluted) | 115.83M |
Key Highlights
- 1EYLEA® net product sales were $561.9 million for the first nine months of 2012, a dramatic increase from $14.9 million in the same period of 2011, highlighting its rapid market adoption and revenue generation potential.
- 2The company achieved profitability, reporting a net income of $279.9 million for the nine months ended September 30, 2012, a significant improvement from a net loss of $168.3 million in the prior year.
- 3Significant collaboration revenues were generated, including a $50.0 million milestone payment from Sanofi for ZALTRAP® approval and a $15.0 million milestone payment from Bayer HealthCare for EYLEA® approval in Japan.
- 4Research and development expenses increased to $444.5 million for the nine months ended September 30, 2012, reflecting continued investment in a diverse pipeline of 12 product candidates, particularly in antibody-based programs.
- 5Total assets grew to $1.66 billion as of September 30, 2012, from $1.32 billion at the end of 2011, supported by an increase in current assets, including significant growth in trade receivables due to EYLEA sales.
- 6The company's cash and marketable securities position remained substantial, with $583.3 million at September 30, 2012, though it decreased from $810.6 million at December 31, 2011, due to increased operational spending and investments.
- 7Ongoing patent litigation with Genentech regarding VEGF Trap technology continues, with a significant $60.0 million payment made to Genentech in Q3 2012 as per a settlement agreement tied to EYLEA® sales.